Aquestive Therapeutics Inc (AQST)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
06-2024 | 03-2024 | 12-2023 | 09-2023 | 06-2023 | |
Sales | 20,099 | 12,053 | 13,206 | 13,002 | 13,241 |
Cost of Goods | 4,526 | 4,389 | 4,679 | 4,798 | 6,617 |
Gross Profit | 15,573 | 7,664 | 8,527 | 8,204 | 6,624 |
Operating Expenses | 16,044 | 17,010 | 13,117 | 11,379 | 11,450 |
Operating Income | 55 | -8,957 | -3,911 | -2,377 | -4,209 |
Interest Expense | 4,195 | 4,200 | 3,235 | 1,312 | 1,428 |
Other Income | 1,395 | 329 | -864 | 1,514 | 129 |
Pre-tax Income | -2,745 | -12,828 | -8,010 | -2,175 | -5,508 |
Income Tax | N/A | N/A | 101 | -140 | 284 |
Net Income Continuous | -2,745 | -12,828 | -8,111 | -2,035 | -5,792 |
Net Income | $-2,745 | $-12,828 | $-8,111 | $-2,035 | $-5,792 |
EPS Basic Total Ops | -0.03 | -0.17 | -0.15 | -0.03 | -0.10 |
EPS Basic Continuous Ops | -0.03 | -0.17 | -0.14 | -0.03 | -0.10 |
EPS Diluted Total Ops | -0.03 | -0.17 | -0.11 | -0.03 | -0.10 |
EPS Diluted Continuous Ops | -0.03 | -0.17 | -0.11 | -0.03 | -0.10 |
EPS Diluted Before Non-Recurring Items | -0.03 | -0.17 | -0.12 | -0.03 | -0.10 |
EBITDA(a) | $2,929 | $-6,077 | $-1,646 | $-2,054 | $-3,861 |